---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-056497"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2026-08-13T12:32:09+00:00"
generated_at: "2026-08-13T12:35:09.213486+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ovid Q2 2026 net loss $15M; soticlestat rights sold to Perceptive NewCo for up to $294.5M milestones

## Summary
- Cash $169.8M at June 30, 2026; runway into 2029.
- Net loss $15.0M ($0.08/share) vs $4.7M ($0.06) in Q2 2025; R&D spend up to $10.0M.
- OV329 Phase 2 FOS study initiated; photosensitivity study testing 5/7/9 mg doses, results near year-end 2026.
- Soticlestat global rights assigned to Perceptive NewCo; Ovid eligible for up to $294.5M milestones plus low-to-mid single-digit royalties.
- Leadership: Kevin Norrett CBO, Charles Carter CFO, Eliseo Salinas R&D Advisor; warrants exercised for ~$53.9M proceeds.

## SEC filing metadata
- accession: 0001628280-26-056497
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2026-08-13T12:32:09+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828026056497/0001628280-26-056497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828026056497/ovid-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-056497
- JSON: https://secwatch.observer/filing/0001628280-26-056497.json
- Plain text: https://secwatch.observer/filing/0001628280-26-056497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.